Literature DB >> 18061194

Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.

Min-Jeong Shin1, Alka M Kanaya, Ronald M Krauss.   

Abstract

BACKGROUND: We tested whether single nucleotide polymorphisms (SNPs) in the PPARalpha gene (PPARA) are associated with variations in levels of plasma apolipoprotein CIII (apoCIII) levels, as well as other lipids and lipoproteins, in African-Americans and Caucasians. METHODS AND
RESULTS: We initially identified an intronic SNP (rs4253728) in PPARA that was associated with plasma apoCIII level (p<0.05) in a subset of 435 individuals from the total study population (n=944; 335 African-Americans and 609 Caucasians). This SNP was then genotyped in a second subset of 476 individuals (total 911 subjects with available data), and a previously described PPARA coding SNP (L162V) which was shown to be in moderate linkage disequilibrium with the intronic SNP (r(2)=0.18) was genotyped in 928 subjects from the same study population. The minor allele frequencies for both SNPs were significantly lower in African-Americans compared with Caucasians (7.2% vs. 27.3% for rs4253728, 1.5% vs. 6.1% for L162V, both p<0.0001). African-Americans had significantly lower levels of TG and apoCIII compared with Caucasians after adjusting for age, sex, body mass index (BMI), waist circumference and other baseline characteristics. However, racial differences in TG levels were attenuated after adjusting for apoCIII levels. The minor alleles for both PPARA SNPs were associated with higher TG and apoCIII levels. Race modified the associations of L162V with TG (p for interaction=0.0056) and apoCIII (p for interaction=0.0011). Levels of both TG and apoCIII were lower in African-American but not Caucasian homozygotes for the major allele compared with carriers of the minor allele. Similar results were obtained for the intronic SNP, but the findings were no longer significant in a model that also contained L162V.
CONCLUSIONS: Two PPARA SNPs, L162V and rs4253728 (intronic), are less prevalent in African-Americans than in Caucasians and in African-Americans only are associated with higher apoCIII and TG levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18061194      PMCID: PMC2678963          DOI: 10.1016/j.atherosclerosis.2007.10.004

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  30 in total

1.  Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

Authors:  J Genest; N H Nguyen; P Theroux; J Davignon; J S Cohn
Journal:  J Cardiovasc Pharmacol       Date:  2000-01       Impact factor: 3.105

2.  Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population.

Authors:  Hermes Florez; Armando Mendez; Paul Casanova-Romero; Carmen Larreal-Urdaneta; Sumaya Castillo-Florez; David Lee; Ronald Goldberg
Journal:  Atherosclerosis       Date:  2005-11-18       Impact factor: 5.162

Review 3.  Selective RXR modulators for the treatment of type II diabetes.

Authors:  Margaret M Faul; Timothy A Grese
Journal:  Curr Opin Drug Discov Devel       Date:  2002-11

4.  Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects.

Authors:  D M Flavell; I Pineda Torra; Y Jamshidi; D Evans; J R Diamond; R S Elkeles; S R Bujac; G Miller; P J Talmud; B Staels; S E Humphries
Journal:  Diabetologia       Date:  2000-05       Impact factor: 10.122

5.  Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.

Authors:  David M Flavell; Yalda Jamshidi; Emma Hawe; Inés Pineda Torra; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Bart Staels; George Miller; Steve E Humphries; Philippa J Talmud; Mikko Syvänne
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

6.  Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study.

Authors:  E S Tai; S Demissie; L A Cupples; D Corella; P W Wilson; E J Schaefer; J M Ordovas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-05-01       Impact factor: 8.311

7.  Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element.

Authors:  Inés Pineda Torra; Yalda Jamshidi; David M Flavell; Jean-Charles Fruchart; Bart Staels
Journal:  Mol Endocrinol       Date:  2002-05

8.  Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus.

Authors:  Y Horikawa; N Oda; N J Cox; X Li; M Orho-Melander; M Hara; Y Hinokio; T H Lindner; H Mashima; P E Schwarz; L del Bosque-Plata; Y Horikawa; Y Oda; I Yoshiuchi; S Colilla; K S Polonsky; S Wei; P Concannon; N Iwasaki; J Schulze; L J Baier; C Bogardus; L Groop; E Boerwinkle; C L Hanis; G I Bell
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

9.  The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.

Authors:  A Sapone; J M Peters; S Sakai; S Tomita; S S Papiha; R Dai; F K Friedman; F J Gonzalez
Journal:  Pharmacogenetics       Date:  2000-06

10.  Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects.

Authors:  Eva-Maria D Nielsen; Lars Hansen; Søren M Echwald; Thomas Drivsholm; Knut Borch-Johnsen; Claus T Ekstrøm; Torben Hansen; Oluf Pedersen
Journal:  Pharmacogenetics       Date:  2003-07
View more
  14 in total

1.  Empirical evidence for "syndrome Z": a hierarchical 5-factor model of the metabolic syndrome incorporating sleep disturbance measures.

Authors:  Nora L Nock; Li Li; Emma K Larkin; Sanjay R Patel; Susan Redline
Journal:  Sleep       Date:  2009-05       Impact factor: 5.849

Review 2.  Pharmacogenetics of posttransplant diabetes mellitus.

Authors:  P Lancia; T Adam de Beaumais; E Jacqz-Aigrain
Journal:  Pharmacogenomics J       Date:  2017-03-28       Impact factor: 3.550

Review 3.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

4.  Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse.

Authors:  Soumen K Manna; Andrew D Patterson; Qian Yang; Kristopher W Krausz; Henghong Li; Jeffrey R Idle; Albert J Fornace; Frank J Gonzalez
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

Review 5.  PPAR-α as a key nutritional and environmental sensor for metabolic adaptation.

Authors:  Alejandra V Contreras; Nimbe Torres; Armando R Tovar
Journal:  Adv Nutr       Date:  2013-07-01       Impact factor: 8.701

6.  Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.

Authors:  Marguerite R Irvin; Qunyuan Zhang; Edmond K Kabagambe; Rodney T Perry; Robert J Straka; Hemant K Tiwari; Ingrid B Borecki; Lawrence C Shimmin; Colin Stuart; Yu Zhong; James E Hixson; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

7.  Intraperitoneal fat and insulin resistance in obese adolescents.

Authors: 
Journal:  Obesity (Silver Spring)       Date:  2009-08-27       Impact factor: 5.002

8.  Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism.

Authors:  Iwona Rudkowska; Christophe Garenc; Patrick Couture; Marie-Claude Vohl
Journal:  Genes Nutr       Date:  2009-07-08       Impact factor: 5.523

9.  Screening of Peroxisome Proliferator-Activated Receptors (PPARs) α, γ and α Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population.

Authors:  Phee-Phee Chia; Sook-Ha Fan; Yee-How Say
Journal:  Ethn Dis       Date:  2015-11-05       Impact factor: 1.847

10.  Genetic variability of RXRB, PPARA, and PPARG in Wegener's granulomatosis.

Authors:  Stefan Wieczorek; Silvia Knaup; Wolfgang L Gross; Jörg T Epplen
Journal:  PPAR Res       Date:  2009-02-11       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.